News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
U.S. Panel Backs Dendreon Corporation’s Provenge for Medicare
November 18, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON (Reuters) - A U.S. advisory panel backed Dendreon Corp's Provenge prostate cancer therapy on Wednesday, telling the Medicare insurance program for the elderly that available data showed it could help patients.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Policy
Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments:
Reuters
June 15, 2026
·
2 min read
·
Nick Paul Taylor
Opinion
The next FDA commissioner must be a champion for gene therapies
June 5, 2026
·
4 min read
·
Erik Paulsen
Policy
FDA taps prior knowledge to expedite cell and gene therapy development
June 3, 2026
·
12 min read
·
BioSpace Editorial Staff
FDA
Unforced errors flummox HHS’ radical transparency bid—again
May 6, 2026
·
6 min read
·
Heather McKenzie
